fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers.

The aims of this study were to assess the effects of a mu-opioid antagonist, naloxone, on endogenous opioid systems and to evaluate the effect of naloxone on the CNS response to mild noxious heat. Doubled-blinded experiments were performed in a cross-over design in 10 healthy male volunteers. Functional magnetic resonance imaging (fMRI) data were collected before and during the infusion and also during thermal stimuli. Increased signal was observed in a number of cortical and subcortical brain regions for naloxone versus saline infusion. Cortical activation was induced in regions including cingulate, prefrontal cortex, and insula. Subcortical regions showing increased signal change included hippocampus and entorhinal cortex. A 46 degrees C stimulus delivered to the back of the hand induced an overall increase in activation in a number of regions in the naloxone group that were not seen in the saline group (e.g., insula, orbitofrontal cortex, thalamus, and hippocampus). These results show that naloxone, even in the absence of psychophysical effects, produces activation in several brain regions that are known to have high levels of mu-opioid receptors and may be involved in endogenous analgesia. Our study is an example of how fMRI can measure subtle changes in brain activation induced by pharmacological agents without cognitive effects.

[1]  R. Bodnar,et al.  Endogenous opiates and behavior: 2002 , 2003, Peptides.

[2]  W. Shoemaker,et al.  The acquisition and maintenance of voluntary ethanol drinking in the rat: effects of dopaminergic lesions and naloxone , 2002, Behavioural Brain Research.

[3]  J. Clark,et al.  Hyperalgesia during opioid abstinence: mediation by glutamate and substance p. , 2002, Anesthesia and analgesia.

[4]  R. Dannals,et al.  Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET) , 2002, Pain.

[5]  Mark R. Symms,et al.  Functional Magnetic Resonance Neuroimaging of Drug Dependence: Naloxone-Precipitated Morphine Withdrawal , 2002, NeuroImage.

[6]  David H Zald,et al.  Somatosensory processing in the human inferior prefrontal cortex. , 2002, Journal of neurophysiology.

[7]  M. Narita,et al.  Suppression of the morphine‐induced rewarding effect in the rat with neuropathic pain: implication of the reduction in µ‐opioid receptor functions in the ventral tegmental area , 2002, Journal of neurochemistry.

[8]  Richard G. Wise,et al.  Combining fMRI with a Pharmacokinetic Model to Determine Which Brain Areas Activated by Painful Stimulation Are Specifically Modulated by Remifentanil , 2002, NeuroImage.

[9]  M. Moser,et al.  Reduced fear expression after lesions of the ventral hippocampus , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  I. Neumann,et al.  Endogenous opioid regulation of stress-induced oxytocin release within the hypothalamic paraventricular nucleus is reversed in late pregnancy: a microdialysis study , 2002, Neuroscience.

[11]  J. B. Justice,et al.  Endogenous opioids in dopaminergic cell body regions modulate amphetamine-induced increases in extracellular dopamine levels in the terminal regions. , 2002, The Journal of pharmacology and experimental therapeutics.

[12]  P. Petrovic,et al.  Placebo and Opioid Analgesia-- Imaging a Shared Neuronal Network , 2002, Science.

[13]  G. Eichenberger,et al.  Neuroanatomical and psychopharmacological evidence for interaction between opioid and GABAergic neural pathways in the modulation of fear and defense elicited by electrical and chemical stimulation of the deep layers of the superior colliculus and dorsal periaqueductal gray matter , 2002, Neuropharmacology.

[14]  S. Clare,et al.  Exacerbation of Pain by Anxiety Is Associated with Activity in a Hippocampal Network , 2001, The Journal of Neuroscience.

[15]  H. Breiter,et al.  Reward Circuitry Activation by Noxious Thermal Stimuli , 2001, Neuron.

[16]  W. Schultz,et al.  Changes in reward‐induced brain activation in opiate addicts , 2001, The European journal of neuroscience.

[17]  Joshua A. Bueller,et al.  Regional Mu Opioid Receptor Regulation of Sensory and Affective Dimensions of Pain , 2001, Science.

[18]  Jean-François Trottier,et al.  Role of endogenous opioid system in the regulation of the stress response , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[19]  K. Britton,et al.  Naloxone blocks ‘anxiolytic’ effects of neuropeptide Y , 2001, Peptides.

[20]  J. Gore,et al.  Activation of the left amygdala to a cognitive representation of fear , 2001, Nature Neuroscience.

[21]  V. Molina,et al.  Early exposure to chronic variable stress facilitates the occurrence of anhedonia and enhanced emotional reactions to novel stressors: reversal by naltrexone pretreatment , 2000, Behavioural Brain Research.

[22]  M Tanaka,et al.  Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. , 2000, European journal of pharmacology.

[23]  P. Matthews,et al.  Learning about pain: the neural substrate of the prediction error for aversive events. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  H. Breiter,et al.  Human brain activation under controlled thermal stimulation and habituation to noxious heat: An fMRI study , 1999, Magnetic resonance in medicine.

[25]  F. Benedetti,et al.  Neuropharmacological Dissection of Placebo Analgesia: Expectation-Activated Opioid Systems versus Conditioning-Activated Specific Subsystems , 1999, The Journal of Neuroscience.

[26]  N. Ramsey,et al.  Naltrexone affects cocaine self-administration in naı̈ve rats through the ventral tegmental area rather than dopaminergic target regions , 1999, European Neuropsychopharmacology.

[27]  T. C. Lima,et al.  Naloxone-induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice , 1998, Neuroscience Letters.

[28]  M. Kreek,et al.  Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. , 1998, Alcoholism, clinical and experimental research.

[29]  G. Scheiber,et al.  Comparison of time course of neuromuscular blockade in young children following rocuronium and atracurium. , 1998, European journal of anaesthesiology.

[30]  H. Fibiger,et al.  Opioid receptor modulation of feeding-evoked dopamine release in the rat nucleus accumbens , 1998, Brain Research.

[31]  M. Moal,et al.  Long‐lasting increased pain sensitivity in rat following exposure to heroin for the first time , 1998, The European journal of neuroscience.

[32]  S. Totterdell,et al.  Topographical organization of projections from the entorhinal cortex to the striatum of the rat , 1997, Neuroscience.

[33]  D. Slaaf,et al.  Skin blood flow abnormalities in a rat model of neuropathic pain: result of decreased sympathetic vasoconstrictor outflow? , 1997, Journal of the autonomic nervous system.

[34]  M A Mintun,et al.  Regional Brain Activity Changes Associated with Fentanyl Analgesia Elucidated by Positron Emission Tomography , 1997, Anesthesia and analgesia.

[35]  Ferenc Gyulai,et al.  Human Brain Activity Response to Fentanyl Imaged by Positron Emission Tomography , 1996, Anesthesia and analgesia.

[36]  Brigitte L. Kieffer,et al.  Recent advances in molecular recognition and signal transduction of active peptides: Receptors for opioid peptides , 1995, Cellular and Molecular Neurobiology.

[37]  G. Pasternak,et al.  Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. , 1995, Trends in pharmacological sciences.

[38]  J. Stamford Descending control of pain. , 1995, British journal of anaesthesia.

[39]  H. Scheich,et al.  Changes in sensitivity of neurons to synaptic actions during imprinting: 19.3 , 1995 .

[40]  R. Bals-Kubik,et al.  Involvement of the mesolimbic dopamine system in mediating the aversive effects of opioid antagonists in the rat , 1995, Behavioural pharmacology.

[41]  H. Akil,et al.  Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study , 1994, The Journal of comparative neurology.

[42]  S. Hyman,et al.  Opioids modulate stress-induced proenkephalin gene expression in the hypothalamus of transgenic mice: A model of endogenous opioid gene regulation by exogenous opioids , 1994, Regulatory Peptides.

[43]  J. Zacny,et al.  Effects of naloxene on the subjective and psychomotor effects of nitrous oxide in humans , 1994, Pharmacology Biochemistry and Behavior.

[44]  M. Chesselet,et al.  Expression of Mu opioid receptor mRNA in rat brain: An in situ hybridization study at the single cell level , 1994, The Journal of comparative neurology.

[45]  H. Fields Pain modulation and the action of analgesic medications , 1994, Annals of neurology.

[46]  E. Paykel,et al.  Effects of naloxone on diurnal rhythms in mood and endocrine function: a dose-response study in man , 1994, Psychopharmacology.

[47]  G. Nappi,et al.  Bilateral sympathetic skin response following nociceptive stimulation: study in healthy individuals. , 1994, Functional neurology.

[48]  J. Ochoa,et al.  Interactions between sympathetic vasoconstrictor outflow and C nociceptor-induced antidromic vasodilatation , 1993, Pain.

[49]  Zhang Jy,et al.  Effects of neuropeptide Y , 1993 .

[50]  Y. Endo,et al.  Increases in Cerebral Blood Flow in Rat Hippocampus After Medial Septal Injection of Naloxone , 1992, Stroke.

[51]  R. Mcmurray,et al.  Effect of 12-hour infusion of naloxone on mood and cognition in normal male volunteers , 1992, Biological Psychiatry.

[52]  J. Roache Performance and physiological measures in abuse liability evaluation. , 1991, British journal of addiction.

[53]  J. Willer,et al.  Diffuse noxious inhibitory controls in man: involvement of an opioidergic link. , 1990, European journal of pharmacology.

[54]  T. Abatzi,et al.  Naloxone does not alter the perception of pain induced by electrical and thermal stimulation of the skin in healthy humans , 1988, Pain.

[55]  C. Kornetsky,et al.  Naloxone attenuation of the effect of cocaine on rewarding brain stimulation. , 1987, Life sciences.

[56]  I. Stolerman Motivational effects of opioids: Evidence on the role of endorphins in mediating reward or aversion , 1985, Pharmacology Biochemistry and Behavior.

[57]  A. Bechara,et al.  Opposite motivational effects of endogenous opioids in brain and periphery , 1985, Nature.

[58]  A. Goldstein,et al.  Partial antagonism of placebo analgesia by naloxone , 1983, Pain.

[59]  J. Panksepp,et al.  Opioid blockade and social comfort in chicks , 1980, Pharmacology Biochemistry and Behavior.

[60]  D. Price,et al.  A psychophysical analysis of experiential factors that selectively influence the affective dimension of pain , 1980, Pain.

[61]  M. Buchsbaum,et al.  Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone , 1979, Psychiatry Research.

[62]  Jaak Panksepp,et al.  Effects of morphine and naloxone on separation distress and approach attachment: Evidence for opiate mediation of social affect , 1978, Pharmacology Biochemistry and Behavior.

[63]  A. Goldstein,et al.  Endorphins: naloxone fails to alter experimental pain or mood in humans. , 1978, Science.

[64]  A. Goldstein,et al.  Effects of naloxone on experimentally induced ischemic pain and on mood in human subjects. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Jacob Jj,et al.  Reversal by naloxone of the effects of morphine on the unanesthetized dog , 1976 .

[66]  O. Wolkowitz,et al.  Naloxone's effect on cognitive functioning in drug-free and diazepam-treated normal humans , 2004, Psychopharmacology.

[67]  M. Buchsbaum,et al.  Pain enhances naloxone-induced hyperalgesia in humans as assessed by somatosensory evoked potentials , 2004, Psychopharmacology.

[68]  E. Rolls,et al.  Abstract reward and punishment representations in the human orbitofrontal cortex , 2001, Nature Neuroscience.

[69]  J. Hollerman,et al.  Involvement of basal ganglia and orbitofrontal cortex in goal-directed behavior. , 2000, Progress in brain research.

[70]  C. Kornetsky Action of opioid drugs on the brain-reward system. , 1995, NIDA research monograph.

[71]  R. Spanagel,et al.  Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[72]  S. Heishman,et al.  Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I. , 1989, The Journal of pharmacology and experimental therapeutics.

[73]  S. Heishman,et al.  Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure. , 1989, The Journal of pharmacology and experimental therapeutics.

[74]  K. Carr The physiology of opiate hedonic effects and the role of opioids in motivated behavior. , 1984, Advances in alcohol & substance abuse.

[75]  Emrich Hm Endorphins in psychiatry. , 1984 .

[76]  H. Emrich Endorphins in psychiatry. , 1984, Psychiatric developments.

[77]  K. Taguchi,et al.  Influence of drugs on evoked potentials in the cat cerebellum: II. Effects of morphine hydrochloride (1). , 1983, Japanese journal of pharmacology.

[78]  W. Haefely Antagonists of benzodiazepines. , 1983, L'Encephale.

[79]  H. Emrich A possible role of opioid substances in depression. , 1982, Advances in biochemical psychopharmacology.

[80]  Emrich Hm A possible role of opioid substances in depression. , 1982 .

[81]  L. Berk,et al.  Endorphins and mood changes in long-distance running. , 1982, Medicine and science in sports and exercise.

[82]  J. Jacob,et al.  [Reversal by naloxone of the effects of morphine on the unanesthetized dog]. , 1976, Archives internationales de pharmacodynamie et de therapie.